Efficacy and Tolerability of Perampanel as Adjunctive Therapy in Chinese Patients With Focal-Onset Seizures: An Observational, Prospective Study

被引:17
|
作者
Zhang, Ranran [1 ]
Qiao, Shan [2 ]
Fang, Xiqin [1 ]
Wang, Kemo [1 ]
Shi, Yanting [1 ]
Du, Qianwen [1 ]
Yang, Tingting [1 ]
Liu, Xuewu [1 ,3 ]
机构
[1] Shandong Univ, Cheeloo Coll Med, Qilu Hosp, Dept Neurol, Jinan, Peoples R China
[2] Shandong First Med Univ, Affiliated Hosp 1, Dept Neurol, Jinan, Peoples R China
[3] Shandong Univ, Inst Epilepsy, Jinan, Peoples R China
来源
FRONTIERS IN NEUROLOGY | 2021年 / 12卷
基金
中国国家自然科学基金;
关键词
epilepsy; anti-seizure medication; focal seizures; perampanel; seizure freedom; ILAE COMMISSION; POSITION PAPER; REAL-LIFE; EPILEPSY; CLASSIFICATION; SAFETY;
D O I
10.3389/fneur.2021.731566
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: To evaluate the efficacy and tolerability of adjunctive perampanel (PER) in Chinese patients with focal-onset seizures, with or without secondarily generalized tonic-clonic seizures.</p> Methods: Fifty-six patients aged 14-72 years were recruited consecutively in this single-center prospective observational study. All patients received PER as add-on treatment on the basis of clinical judgment. Seizure frequency, adverse events (AEs), and retention rates were obtained at 3 and 6 months after PER introduction.</p> Results: The overall response rates were 60 and 71.1% after 3 and 6 months, respectively, and the freedom of seizures at the same points were reached in 8 and 15.8%. The retention rates were 89.3% at the 3-month follow-up and 67.9% at the 6-month follow-up. The overall incidence of adverse events was 55.4%. The leading reported AEs were dizziness (39.3%) and somnolence (25%).</p> Conclusions: Our study confirmed the efficacy and tolerability of adjunctive PER in Chinese patients in real-life conditions. Based on our treatment experience, a lower maintenance dose of PER would be needed in Chinese patients.</p>
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Efficacy and tolerability of lacosamide as adjunctive therapy in patients with focal-onset seizures: an observational, prospective study
    Jin, Yang
    Zhang, Ranran
    Jiang, Jing
    Liu, Xuewu
    ACTA NEUROLOGICA BELGICA, 2023, 123 (03) : 1081 - 1087
  • [2] Efficacy and tolerability of lacosamide as adjunctive therapy in patients with focal-onset seizures: an observational, prospective study
    Yang Jin
    Ranran Zhang
    Jing Jiang
    Xuewu Liu
    Acta Neurologica Belgica, 2023, 123 : 1081 - 1087
  • [3] Effectiveness and safety of perampanel as adjunctive therapy among Chinese patients with focal-onset epilepsy: A real-world prospective observational study
    Wang, Qinyue
    Xu, Ye
    Chen, Yuncan
    Wu, Xunyi
    Ge, Yan
    Zhu, Guoxing
    EPILEPSY & BEHAVIOR, 2022, 136
  • [4] Efficacy and safety of perampanel monotherapy in Chinese patients with focal-onset seizures: A single-center, prospective, real-world observational study
    Ma, Haiyan
    Zhu, Haitao
    Chen, Fangqing
    Yang, Yiqing
    Qu, Xuefeng
    Xu, Honghao
    Yang, Lu
    Zhang, Rui
    EPILEPSIA OPEN, 2023, 8 (04) : 1474 - 1483
  • [5] FAME study: Efficacy and safety of perampanel as first adjunctive therapy after first or second monotherapy in patients with focal-onset seizures
    Kim, Ji Hyun
    Kim, Dong Wook
    Dash, Amitabh
    Lee, JiWoong
    Malhotra, Manoj
    EPILEPSIA, 2021, 62 : 43 - 43
  • [6] The efficacy and safety of adjunctive perampanel for the treatment of refractory focal-onset seizures in patients with epilepsy: A meta-analysis
    Li, Yiming
    Zeng, Ya
    Mu, Jie
    Zhou, Dong
    EPILEPSIA OPEN, 2022, 7 (02) : 271 - 279
  • [7] Final results of a mirroring clinical practice study of perampanel in adults and adolescents: A real-life, observational study of adjunctive perampanel for focal-onset seizures
    Gentile, A.
    Di Gennaro, G.
    D'Aniello, A.
    Goldman, S.
    Patten, A.
    Chiacchiaretta, M.
    EPILEPSIA, 2022, 63 : 128 - 128
  • [8] Efficacy/Safety of Low-/High-Dose Perampanel as First Adjunctive Therapy in Patients With Focal-Onset Seizures: Post Hoc Analysis of the FAME Study
    Seo, Dae Won
    Lee, JiWoong
    Dash, Amitabh
    Lee, Sang Kun
    Lee, Sang-Ahm
    Malhotra, Manoj
    EPILEPSIA, 2021, 62 : 51 - 51
  • [9] A phase IV, prospective, post-approval study of adjunctive perampanel in indian patients aged ≥12 Years with focal-onset seizures: Study 508
    Rohatgi, Anshu
    Ravat, Sangeeta
    Patil, Balaji
    Dash, Amitabh
    Malhotra, Manoj
    EPILEPSIA, 2021, 62 : 48 - 48
  • [10] Clinical Factors Associated with Response to Perampanel as First Adjunctive Treatment in Patients with Focal-Onset Seizures (FOS) in the FAME study
    Lee, JiWoong
    Kim, Dong Wook
    Seo, Dae Won
    Dash, Amitabh
    Malhotra, Manoj
    EPILEPSIA, 2021, 62 : 52 - 52